

Serial No.: 10/594,293
Group Art Unit No.: 1643

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Cancelled)

3. (Previously Presented) An isolated therapeutic antibody that specifically binds to OSM, and modulates the interaction between OSM and gp130 comprising:

CDRH1 of SEQ.I.D.NO: 1,
CDRH2 of SEQ.I.D.NO: 2,
CDRH3 of SEQ.I.D.NO: 3,
CDRL1 of SEQ.I.D.NO: 4,
CDRL2 of SEQ.I.D.NO: 5, and
CDRL3 of SEQ.I.D.NO: 6.

4-5. (Cancelled)

6-13. (Cancelled)

14. (Previously Presented) The therapeutic antibody of claim 3, which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a V_H domain of SEQ.I.D.NO: 9 and a V_L domain of SEQ.I.D.NO: 10.

15. (Previously Presented) The therapeutic antibody of claim 3, which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a heavy chain of SEQ.I.D.NO: 11 and a light chain of SEQ.I.D.NO: 12.

16-78. (Cancelled)

Serial No.: 10/594,293
Group Art Unit No.: 1643

79. (New) The isolated therapeutic antibody according to Claim 3, wherein the antibody is selected from the group consisting of: an intact antibody, a chimaeric antibody, a humanized antibody, a bispecific antibody, and a heteroconjugate antibody.

80. (New) The isolated therapeutic antibody according to Claim 3, wherein the antibody is an intact antibody.

81. (New) The antibody according to Claim 80, wherein the intact antibody is selected from the group consisting of: a murine intact antibody, a rat intact antibody, a rabbit intact antibody, a primate intact antibody, and a human intact antibody.

82. (New) The antibody according to Claim 80, wherein the intact antibody is a human intact antibody.

83. (New) The isolated therapeutic antibody according to Claim 3, wherein the antibody is a chimaeric antibody.

84. (New) The isolated therapeutic antibody according to Claim 3, wherein the antibody is a humanized antibody.

85. (New) The antibody of claim 80, wherein the intact antibody is humanized.

86. (New) The isolated therapeutic antibody according to Claim 3, further comprising a human heavy chain constant region selected from the group consisting of; IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, and IgM.

87. (New) The isolated therapeutic antibody according to Claim 86, wherein the constant region is of an IgG isotype.

Serial No.: 10/594,293
Group Art Unit No.: 1643

88. (New) The isolated therapeutic antibody according to Claim 87, wherein the constant region is IgG1.

89. (New) The isolated therapeutic antibody according to Claim 88, wherein the constant region is mutated to render the antibody non-lytic.

90. (New) The isolated therapeutic antibody according to Claim 3, wherein said antibody modulates an interaction between Site II of hOSM and gp130.

91. (New) The isolated therapeutic antibody according to Claim 90, wherein said antibody inhibits said interaction.

92. (New) The isolated therapeutic antibody according to Claim 90, wherein said antibody blocks said interaction.

93. (New) An antigen binding fragment of the isolated therapeutic antibody according to Claim 3.

94. (New) The antigen binding fragment according to Claim 93, wherein said fragment is selected from the group consisting of: Fab, Fab', Fd, F(ab)₂, and ScFv.

95. (New) A pharmaceutical composition comprising an isolated therapeutic antibody according to Claim 3.

96. (New) A pharmaceutical composition comprising an antigen binding fragment of the isolated therapeutic antibody according to Claim 3.

97. (New) An isolated therapeutic antibody according to Claim 3, wherein said antibody is capable of binding hOSM and cOSM.

Serial No.: 10/594,293

Group Art Unit No.: 1643

98. (New) The isolated therapeutic antibody according to Claim 3, wherein said OSM is human OSM.